Ascites is a pathologic collection of fluid in the peritoneal cavity. The most common cause is cirrhosis, which accounts for approximately 75% of cases, followed by congestive heart failure and malignant ascites.[1]
- 0
Summary
Clinical features
Patients present with abdominal distension; fluid may be detected on physical examination with shifting dullness. Ultrasound, computed tomography scan, or magnetic resonance imaging can confirm the diagnosis. In the majority of patients, history and examination will provide important clues as to the etiology of ascites (e.g., signs of chronic liver disease or cardiac failure). Causes include diseases that lead to portal hypertension, hypoalbuminemia, and neoplasms.
Cirrhosis
In 2017, cirrhosis caused more than 1.32 million deaths globally.[2] Deaths due to cirrhosis constituted 2.4% of total deaths globally in 2017 compared with 1.9% in 1990.[2] Chronic liver disease and cirrhosis account for approximately 2 million deaths annually worldwide.[3]
In cirrhosis, development of hepatic fibrosis from chronic, recurrent hepatocyte injury leads to disruption in the intrahepatic circulation. This causes increased hepatic resistance to portal flow, resulting in the development of portal hypertension, and subsequent collateral vein formation and shunting of blood to the systemic circulation.[4]
Ascites forms due to both renal dysfunction and the abnormalities in the portal and splanchnic circulation.[4] [5] The chronic hepatic injury results in the release of nitric oxide, promoting splanchnic arterial vasodilation. This vasodilation causes activation of the renin angiotensin system, sympathetic nervous system, and antidiuretic hormone (ADH), to mitigate low circulatory volume. Release of ADH leads to retention of both sodium and water, resulting in the formation of ascites.[6] Dilutional hyponatremia, arising from impaired renal excretion of free water, is a marker of more advanced liver disease.[1] [7]
Other causes
Other causes of portal hypertension that may be associated with ascites include congestive heart failure, constrictive pericarditis, alcohol-related liver disease, fulminant hepatitis, subacute hepatitis, massive liver metastasis, and Budd-Chiari syndrome.
Conditions causing hypoalbuminemia such as nephrotic syndrome and protein-losing enteropathy may result in ascites. Peritoneal diseases including infectious peritonitis and malignancies can also cause ascites.
Last updated
Library
Citations
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.[Abstract][Full Text]
Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.[Abstract][Full Text]
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417[Full Text]
1. Krige JEJ, Beckingham IJ. Clinical review: ABC of disease of liver, pancreas and biliary system. Portal hypertension-2. Ascites, encephalopathy and other conditions. BMJ. 2001 Feb 17;322(7283):416-8.[Abstract][Full Text]
2. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-66.[Abstract][Full Text]
3. Kim D, Bonham CA, Konyn P, et al. Mortality trends in chronic liver disease and cirrhosis in the United States, before and during COVID-19 pandemic. Clin Gastroenterol Hepatol. 2021 Dec;19(12):2664-66.e2.[Abstract][Full Text]
4. Ginès P, Cardenas A., Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med. 2004 Apr 15;350(16):1646-54.[Abstract]
5. Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014 May;18(2):281-91.[Abstract][Full Text]
6. Alukal JJ, John S, Thuluvath PJ. Hyponatremia in cirrhosis: an update. Am J Gastroenterol. 2020 Nov;115(11):1775-85.[Abstract]
7. Praharaj DL, Anand AC. Clinical implications, evaluation, and management of hyponatremia in cirrhosis. J Clin Exp Hepatol. 2022 Mar-Apr;12(2):575-94.[Abstract][Full Text]
8. Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 2021 Jul;75(suppl 1):S49-66.[Abstract][Full Text]
9. Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy. JHEP Rep. 2021 Aug;3(4):100316.[Abstract][Full Text]
10. Sikuler E, Ackerman Z, Braun M, et al. Guidelines for diagnosis and management of cirrhotic ascites and its complications. The Israeli Association for the Study of the Liver [in Hebrew]. Harefuah. 2012 Dec;151(12):705-8.[Abstract]
11. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-60.[Abstract][Full Text]
12. Royal College of Obstetricians and Gynaecologists. Management of ascites in ovarian cancer patients. Nov 2014 [internet publication].[Full Text]
13. Elkassem S, Dixon E, Conly J, et al. Primary peritonitis in a young healthy woman: an unusual case. Can J Surg. 2008 Apr;51(2):E40-1.[Abstract][Full Text]
14. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992 Aug 1;117(3):215-20.[Abstract]
15. Veldhuijzen van Zanten D, Buganza E, Abraldes JG. The role of hepatic venous pressure gradient in the management of cirrhosis. Clin Liver Dis. 2021 May;25(2):327-43.[Abstract]
16. Ricart E, Soriano G, Novella MT, et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol. 2000 Apr;32(4):596-602.[Abstract]
17. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology. 1985 May-Jun;5(3):457-62.[Abstract]
18. Chen TA, Lo GH, Lai KH, et al. Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics. World J Gastroenterol. 2005 Nov 21;11(43):6823-7.[Abstract][Full Text]
19. Angeli P, Guarda S, Fasolato S, et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther. 2006 Jan 1;23(1):75-84.[Abstract][Full Text]
20. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.[Abstract][Full Text]
21. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.[Abstract][Full Text]
22. Rimola A, García-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000 Jan;32(1):142-53.[Abstract][Full Text]
23. Akriviadis EA. Hemoperitoneum in patients with ascites. Am J Gastroenterol. 1997 Apr;92(4):567-75.[Abstract]
24. Tapping CR, Ling L, Razack A. PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success. Br J Radiol. 2012 May;85(1013):623-8.[Abstract][Full Text]
25. Martin LG. Percutaneous placement and management of the Denver shunt for portal hypertensive ascites. AJR Am J Roentgenol. 2012 Oct;199(4):W449-53.[Abstract][Full Text]
26. Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020 Sep 14;370:m2687.[Abstract]
27. Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017 Sep 27;(9):CD011532.[Abstract][Full Text]
28. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008 May;134(5):1360-8.[Abstract][Full Text]
29. Zhai M, Liu Z, Long J, et al. The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Sci Rep. 2021 Mar 4;11(1):5195.[Abstract][Full Text]
30. Kim WR, Brown RS Jr, Terrault NA, et al. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002 Jul;36(1):227-42.[Abstract]
31. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013 Mar;58(3):593-608.[Abstract]
32. Cattau E, Benjamin SB, Knuff TE, et al. The accuracy of the physical exam in the diagnosis of suspected ascites. JAMA. 1982 Feb 26;247(8):1164-6.[Abstract]
33. Light, RW. Clinical practice. Pleural effusion. N Engl J Med. 2002 Jun 20;346(25):1971-7.[Abstract]
34. Inadomi J, Cello JP, Koch J. Ultrasonographic determination of ascitic fluid. Hepatology. 1996 Sep;24(3):549-51.[Abstract]
35. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003 Jul;38(1):258-66.[Abstract]
36. Krige JE, Beckingham IJ. Clinical review: ABC diseases of liver, pancreas and biliary system. Portal hypertension - 1: varices. BMJ. 2001 Feb 10;322(7282):348-51.[Abstract][Full Text]
37. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417[Full Text]
38. Sakai H, Sheer TA, Mendler MH, et al. Choosing the location for non-image guided abdominal paracentesis. Liver Int. 2005 Oct;25(5):984-6.[Abstract]
39. Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther. 2005 Mar 1;21(5):525-9.[Abstract][Full Text]
40. Rowley MW, Agarwal S, Seetharam AB, et al. Real-time ultrasound-guided paracentesis by radiologists: near zero risk of hemorrhage without correction of coagulopathy. J Vasc Interv Radiol. 2019 Feb;30(2):259-64.[Abstract]
41. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Jan;73(1):366-413.[Abstract][Full Text]
42. O'Leary JG, Greenberg CS, Patton HM, et al. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology. 2019 Jul;157(1):34-43.e1.[Abstract][Full Text]
43. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48.[Abstract][Full Text]
44. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.[Abstract][Full Text]
45. Bernardi M, Caraceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81.[Abstract][Full Text]
46. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.[Abstract][Full Text]
47. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol. 2000 Jan;32(1):142-53.[Abstract]
48. Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024 May 1;79(5):1180-211.[Abstract][Full Text]
49. Walsh K, Alexander G. Alcoholic liver disease. Postgrad Med J. 2000 May;76(895):280-6.[Abstract][Full Text]
50. Tenner S, Vege SS, Sheth S, et al. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2024 Mar 1;119(3):419-37.[Abstract][Full Text]
51. American Society for Clinical Pathology. Testing for amylase. Choosing Wisely, an initiative of the ABIM Foundation. 14 Sep 2016 [internet publication].
52. Rompianesi G, Hann A, Komolafe O, et al. Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis. Cochrane Database Syst Rev. 2017 Apr 21;(4):CD012010.[Abstract][Full Text]
53. Leppäniemi A, Tolonen M, Tarasconi A, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019;14:27.[Abstract][Full Text]
54. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013 Jul-Aug;13(4 suppl 2):e1-15.[Abstract][Full Text]
55. American College of Radiology. ACR appropriateness criteria: acute pancreatitis. 2019 [internet publication].[Full Text]
56. Bohte AE, van Werven JR, Bipat S, et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011 Jan;21(1):87-97.[Abstract][Full Text]
57. Wattacheril JJ, Abdelmalek MF, Lim JK, et al. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023 Oct;165(4):1080-8.[Abstract][Full Text]
58. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542.[Abstract][Full Text]
59. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 May 1;77(5):1797-835.[Abstract][Full Text]
60. National Institute for Health and Care Excellence. Cirrhosis in over 16s: assessment and management. Sep 2023 [internet publication].[Full Text]
61. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011 Mar;33(5):525-40.[Abstract][Full Text]
62. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021 Sep;75(3):659-89.[Abstract][Full Text]
63. American College of Radiology. ACR appropriateness criteria: chronic liver disease. 2019 [internet publication].[Full Text]
64. Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017 Feb;152(3):598-607.e2.[Abstract][Full Text]
65. Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2023 Apr 1;77(4):1428-55.[Abstract][Full Text]
66. Merle U, Eisenbach C, Weiss KH, et al. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson's disease. J Hepatol. 2009 Nov;51(5):925-30.[Abstract][Full Text]
67. Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med. 2004 Feb 5;350(6):578-85.[Abstract]
68. Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med. 2002 Apr 18;346(16):1212-20.[Abstract]
69. Mills JA. Systemic lupus erythematosus. N Engl J Med. 1994 Jun 30;330(26):1871-9.[Abstract]
70. al Karawi MA, Mohamed AE, Yasawy MI, et al. Protean manifestation of gastrointestinal tuberculosis: report on 130 patients. J Clin Gastroenterol. 1995 Apr;20(3):225-32.[Abstract]
